Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2015

View Archived Issues

BMS initiates phase I trial of BMS-986171

Blood level of UCH-L1 is a biomarker of traumatic brain injury

Researchers at CSIC present alpha-synuclein overexpressing mouse model

miRagen Therapeutics begins first clinical trial for antifibrosis candidate MRG-201

Protein Sciences receives U.S. Department of Defense grant to develop adenovirus vaccine

Enterome Bioscience and Gustave Roussy establish microbiome collaboration in immune-oncology

Daratumumab granted U.S. orphan status for diffuse large B-cell lymphoma

The FDA grants orphan drug designation to Bone Therapeutics' bone marrow derived cells

Early clinical data for Macrogenics' MGA-271

Daiichi Sankyo presents preclinical and phase I results for DS-3032b

Amplyx Pharmaceuticals secures funding to advance APX-001

FDA approves Tagrisso to treat certain patients with NSCLC

SOM Biotech and Vall d'Hebron complete trial in patients with TTR amyloidosis

Genfit reveals design of phase III trial of elafibranor for NASH

Finnish clearance for first-in-human study of Lymfactin for breast cancer-associated lymphedema

Auven releases promising findings from pivotal study of Seciera for dry eye disease

Two Baxalta hemophilia A products approved in Europe, U.S.

Preclinical data on TBI-302 that led to advancement into phase I for HCC

Abeta42-targeting MAb MEDI-1814 well tolerated in patients with Alzheimer's disease

Piramal Enterprises reports cannabinoid CB1 receptor antagonists

Isis Pharmaceuticals describes gapped oligonucleotides

Mitsubishi Tanabe Pharma presents ENPP2 inhibitors

Merck & Co. and Mochida Pharmaceutical divulge FIXa inhibitors

NIP-565: a JAK-1 inhibitor for rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...